NeoTract said today that it logged several reimbursement wins for its UroLift treatment for enlarged prostates, including a Medicare contractor and at least 7 independent insurers.
The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate.
Today NeoTract said Medicare contractor National Government Services agreed to cover UroLift patients in Connecticut, Illinois, Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont and Wisconsin.
Private insurers Kaiser Permanente, SelectHealth and Blue Cross Blue Shield plans including CareFirst, Highmark, Louisiana, Nebraska and South Carolina also added coverage for the prostate treatment, the Pleasanton, Calif.-based company said.
“Thanks to the rigorous clinical data, widespread adoption, and enthusiastic support from the urologic community, the UroLift prostatic urethral lift is a proven treatment option for millions of men suffering from enlarged prostate issues,” president & CEO Dave Amerson said in prepared remarks. “We are delighted that commercial insurers and independent networks as well as Medicare and Medicaid have acknowledged that the UroLift system offers an early treatment option that is minimally invasive and cost-effective for men that are not well served by medical therapy.”
The Centers for Medicare & Medicaid Services granted coverage for UroLift effective Jan. 1, 2015.
In May, NeoTract released data from 2 randomized UroLift studies, touting “excellent” durability after 4 years.